Search clinical trials for: mRNA-1273 vaccine
Total 10199 results
-
ModernaTX, Inc.CompletedSARS-CoV-2United States
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.Active, not recruitingCytomegalovirus | SARS-CoV-2 | Seasonal Influenza | Respiratory Syncytial VirusUnited States
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.CompletedInfluenza | SARS-CoV-2United States
-
National Institute of Allergy and Infectious Diseases...ModernaTX, Inc.CompletedCOVID-19 | COVID-19 ImmunisationUnited States
-
Korea University Guro HospitalKorea University Anam Hospital; Ajou University School of Medicine; Korean Center... and other collaboratorsRecruitingCOVID-19 | Vaccine Adverse Reaction | Vaccine Immune ResponseKorea, Republic of
-
Universiteit AntwerpenCompletedCOVID-19 | Coronavirus Disease 2019Belgium
-
University Medical Center GroningenActive, not recruiting
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.Completed
-
National Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma | Hematologic Malignancy | Solid Tumor MalignancyUnited States
-
Umeå UniversityNot yet recruitingCovid19 | Vaccination; Infection
-
ModernaTX, Inc.Biomedical Advanced Research and Development AuthorityCompleted
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruiting
-
ModernaTX, Inc.Active, not recruiting
-
Sheba Medical CenterModernaTX, Inc.CompletedCOVID-19 | SARS CoV 2 Infection | COVID-19 Pandemic | ImmunogenicityIsrael
-
National Institute of Allergy and Infectious Diseases...ModernaTX, Inc.CompletedCOVID-19 | COVID-19 ImmunisationUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteModernaTX, Inc.CompletedCovid19 | SARS-CoV2 InfectionUnited States
-
ModernaTX, Inc.Biomedical Advanced Research and Development AuthorityActive, not recruitingSARS-CoV-2United States, Dominican Republic
-
Sinocelltech Ltd.Not yet recruiting
-
National Institute of Allergy and Infectious Diseases...CompletedCovid19 | SARS-CoV2 InfectionUnited States
-
ModernaTX, Inc.National Institute of Allergy and Infectious Diseases (NIAID); Biomedical Advanced...Completed
-
Assistance Publique - Hôpitaux de ParisCOVIREIVACActive, not recruitingAdult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second DoseFrance
-
National Institute of Allergy and Infectious Diseases...CompletedSARS-CoV-2 InfectionUnited States
-
University Medical Center GroningenRadboud University Medical Center; Erasmus Medical Center; Academisch Medisch... and other collaboratorsCompletedKidney Diseases | Covid19 | SARS-CoV2 Infection | Vaccine Response ImpairedNetherlands
-
University of California, Los AngelesModernaTX, Inc.CompletedSARS-CoV-2 | Immunosuppression | Lung Transplant RecipientUnited States
-
National Institute of Allergy and Infectious Diseases...PPDCompleted
-
ModernaTX, Inc.Recruiting
-
Oliver Cornely, MDEuropean Commission; VACCELERATECompletedCOVID-19 | Vaccination; Infection | Vaccination ReactionSpain, Ireland, Germany, Norway, Lithuania
-
ModernaTX, Inc.Active, not recruiting
-
Leiden University Medical CenterRecruitingCOVID-19 | Vaccination; InfectionNetherlands
-
Medical University of ViennaActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...CompletedCOVID-19United States
-
Regeneron PharmaceuticalsCompletedHealthy | Chronic Stable IllnessUnited States
-
ModernaTX, Inc.Lead Scientific and Operating Center: Julius Clinical ResearchActive, not recruitingMyocarditis, PericarditisDenmark, Norway, Spain, United Kingdom
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Active, not recruitingCOVID-19 | Breakthrough InfectionTaiwan
-
ModernaTX, Inc.RecruitingSARS-CoV-2Korea, Republic of
-
ModernaTX, Inc.Terminated
-
Chulalongkorn UniversityBioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaboratorsRecruitingSafety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditionsThailand
-
ModernaTX, Inc.Active, not recruiting
-
ModernaTX, Inc.Completed
-
McMaster UniversityUniversity of Manitoba; University of Alberta; University of SaskatchewanWithdrawn
-
University Hospital, CaenCompleted
-
Masaryk UniversityRecruitingAdverse Reaction to Vaccine | COVID19 VaccinePoland, Canada, United States, Croatia, Czechia, Estonia, Ethiopia, Germany, Ghana, Mexico, Portugal, Russian Federation, Serbia, Slovenia